Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
复制标题
DOI：
10.1016/j.cardfail.2011.10.015
复制
发表时间：
2012-02-01
影响因子：
6
通讯作者：
Faggiano, Pompilio
中科院分区：
文献类型：
--
作者：
Tarantini, Luigi;Cioffi, Giovanni;Faggiano, Pompilio
背景：辅助性曲妥珠单抗治疗可提高早期乳腺癌(EBC)人表皮生长因子受体2(HER2)阳性妇女的存活率。由于曲妥珠单抗潜在的心脏毒性，需要仔细监测心功能。方法和结果：2008年1月至2009年6月期间，共有499名HER2阳性的EBC患者在意大利10家医疗机构接受曲妥珠单抗治疗，为期一年。我们评估了与心动过敏症相关的发病率、发生时间和临床特征。在曲妥珠单抗治疗前、治疗后3、6、9和12个月用超声心动图测定左心室射血分数(LVEF)。133名患者(27%)发现了妥泰：102名(20%)患者的LVEF无症状地下降了10%，但20%或
Background: Adjuvant trastuzumab therapy improves survival of human epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). A careful monitoring of cardiac function is needed due to potential trastuzumab cardiotoxicity (Tcardiotox). To date, the incidence, timing, and phenotype of patients with Tcardiotox in clinical practice are not well known.Methods and Results: A total of 499 consecutive HER2-positive women (mean age 55 +/- 11 years) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed for 1 year. We evaluated incidence, time of occurrence, and clinical features associated with Tcardiotox. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and at 3, 6, 9, and 12 months during trastuzumab therapy. Tcardiotox was recognized in 133 patients (27%): 102 (20%) showed asymptomatic reduction in LVEF of > 10% but 20% or